Objectives: The aims of this study are to describe two patients whose manic symptoms persisted for several months after the cessation of corticosteroids, to review the literature and to suggest treatment.
Methods: The presentation of two elderly patients with persistent manic symptoms following cessation of corticosteroids several months previously afforded the author the opportunity to examine them carefully, investigate and treat them.
Results: The patients were investigated to rule out other causes and were treated with sodium valproate and quetiapine (in the second patient). When well, the medications were slowly decreased and stopped. Both patients were well at one-year follow-up.
Conclusions: Manic symptoms may persist for many months after stopping corticosteroids and active treatment is needed to control them.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1039856218758566 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and Dermoscopic Evaluation of Patients With Topical Steroid Damaged Faces (TSDF).
Cureus
November 2024
Dermatology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Ambala, IND.
Background Topical steroid-dependent or damaged face (TSDF) is a common condition where the widespread availability of over-the-counter topical corticosteroid (TCS)-containing products leads to their misuse and addiction. Prolonged use of these steroids on the face can result in significant side effects. Early diagnosis and cessation of steroid use are important.
View Article and Find Full Text PDFEfficacy of Epinastine Eyelid Cream in Pediatric Vernal Keratoconjunctivitis: A Case Report.
Cureus
November 2024
Ophthalmology, Mamoto Eye Clinic, Higashi-Osaka, JPN.
Allergic conjunctivitis (AC) is characterized by inflammatory responses in the conjunctiva and is often complicated by atopic dermatitis and mechanical irritation. Vernal keratoconjunctivitis (VKC), a severe subtype of AC, presents unique challenges in its diagnosis and management, particularly in pediatric patients. This case report describes an eight-year-old girl with VKC who exhibited poor adherence to a prescribed regimen of 0.
View Article and Find Full Text PDFTocilizumab for Cystoid Macular Edema Secondary to Immune Recovery Uveitis in a Patient with Contraindications to Long-Term Systemic Corticosteroid.
Yale J Biol Med
December 2024
Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Palo Alto, CA, USA.
: To report a case of cystoid macular edema (CME) secondary to immune recovery uveitis (IRU) in a patient with previous history of cytomegalovirus (CMV) retinitis and leukemia, which was successfully treated with tocilizumab (TCZ), an interleukin-6 (IL-6) receptor antagonist. : The clinical records of the case were reviewed, focusing on demographics, image findings, and clinical course. : A 17-year-old female with a past medical history of T-cell acute lymphoblastic leukemia (T-ALL) undergoing chemotherapy for two years presented with active CMV retinitis.
View Article and Find Full Text PDFSuccessful Treatment of Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature.
Clin Cosmet Investig Dermatol
December 2024
Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, 510095 People's Republic of China.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by enhancing the immune system's ability to target cancer cells. However, ICIs can lead to immune-related adverse events (irAEs), including dermatologic manifestations such as bullous pemphigoid (BP).
Objective: To evaluate the efficacy and safety of omalizumab and other biologics in the treatment of ICI-induced refractory bullous pemphigoid and to derive a strategy for selecting biologic treatments for this condition.
Efficacy and safety of azathioprine in patients with Cronkhite-Canada syndrome: a case series from Peking Union Medical College Hospital.
BMC Pharmacol Toxicol
December 2024
Department of Gastroenterology, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.
Background: Cronkhite-Canada syndrome (CCS) is a rare non-hereditary chronic inflammatory disease characteristic of gastrointestinal polyps and ectodermal abnormalities. Corticosteroid therapy is the mainstay medication for CCS. Few studies indicated immunosuppressants might be the choices for patients with steroid refractory, steroid dependent or intolerant.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!